|
|
|
市場調查報告書
放射性醫藥品的全球市場
Radiopharmaceuticals
|
放射性醫藥品的全球市場 是由出版商Global Industry Analysts, Inc.在2011年10月所出版的。
這份英文市場調查報告書包含Pages: 373 價格從美金4500起跳。
本報告提供全球放射性醫藥品市場相關分析，美國，歐洲的各分類市場趨勢，2009∼2017年預測，加入此市場的主要企業簡介等彙整資料，為您概述為以下內容。
第1章 簡介·調查手法·產品定義
第2章 產業概要
- 概要
- 市場方案:檢討
- 不景氣時的回顧
- 今後預測
- 主要的市場趨勢
- 與癌症持續不斷的戰鬥:促進成長要素
- 促進成長的新制診斷藥物的開發
- 放射性同位素的個體化醫療的到來
- 人口統計與新的應用機會的產生
- 費用效果的重新認識
- 醫生和患者的認識擴大
- 分子影像平台的擴大
- 促進需求的PET需求擴大
- SPECT/電腦斷層掃描及PET/電腦斷層掃描的引進
- 治療用放射性醫藥品的有潛力的開發
- 國際合作
- 市場課題
- 藥物開發成本高
- 供不應求
- 價格敏感性和替代品的競爭限制市場潛力
- 兒童患者劑量缺乏標準限制放射性藥物的有效性
- 對輻射的未知恐懼阻礙成長
- 發展中國家的問題
第3章 產品概要
- 核子醫學掃描術:概要
- 放射性醫藥品:定義
- 作用機制
- 放射性醫藥品的用途
- 放射性醫藥品的分類
- 診斷用放射性醫藥品
- 一般所採用的診斷用放射性藥物
- 主要的同位元素和診斷的應用
- 放射性醫藥品診斷的核醫學模式
- 治療用放射性醫藥品
- 治療用放射性醫藥品的特徵
- 一般所採用的治療用放射性醫藥品
第4章 產品核可·引進
第5章 近幾年的產業活動
第6章 主要企業
- Actinium Pharmaceuticals, Inc.
- Advanced Medical Isotope Corporation
- Alseres Pharmaceuticals, Inc
- Bayer HealthCare Pharmaceuticals
- Bio-Nucleonics, Inc.
- Bracco Diagnostics, Inc.
- Cardinal Health, Inc
- Covidien Imaging Solutions
- EUSA Pharma (Europe) Ltd.
- Jubilant DraxImage Inc.
- GE Healthcare Limited
- GlaxoSmithKline Plc
- IBA Group
- Immunomedics, Inc.
- Lantheus Medical Imaging, Inc
- Nordion
- Molecular Insight Pharmaceuticals, Inc.
- Novelos Therapeutics Inc
- Peregrine Pharmaceuticals, Inc.
- PETNET Pharmaceuticals, Inc.
- Pharmalucence, Inc.
- Spectrum Pharmaceuticals, Inc.
- Triad Isotopes, Inc.
第7章 全球市場預測
第8章 美國市場
第9章 加拿大市場
第10章 日本市場
第11章 歐洲市場
第12章 亞太地區市場
第13章 其他的市場
Abstract
This report analyzes the US and the European markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 65 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bio-Nucleonics, Inc., Bracco Diagnostics, Inc., Cardinal Health, Inc., Cellectar, LLC., Cell Therapeutics, Inc., Covidien Imaging Solutions, EUSA Pharma (Europe) Ltd., Jubilant DraxImage Inc., GE Healthcare Limited, GlaxoSmithKline Plc, IBA Group, Immunomedics, Inc., Lantheus Medical Imaging, Inc, Nordion, Molecular Insight Pharmaceuticals, Inc., Novelos Therapeutics Inc., Peregrine Pharmaceuticals, Inc., PETNET Pharmaceuticals, Inc., Pharmalucence, Inc., Spectrum Pharmaceuticals, Inc., and Triad Isotopes, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- A. Diagnostic Radiopharmaceuticals
- B. Therapeutic Radiopharmaceuticals
2. INDUSTRY OVERVIEW
- A Quick Primer
- Market Scenario: A Review
- Recession Impact in Retrospect
- Outlook
- Key Market Trends
- Continuous Battle Against Cancer: A Key Driver for Growth
- Cancer Statistics: A Grim Prognosis
- Business Case for Radiopharmaceuticals Exemplified
- Development of Newer Diagnostic Agents to Boost Growth
- Emergence of Radioisotope Based Personalized Therapy
- Demographics & New Applications Offer Opportunities On a Platter
- Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
- Widespread Awareness Among Practitioners & Patients: The Need of the Hour
- Expansion of Molecular Imaging Platform is Key to Future Growth
- Molecular Imaging Agents: A Noteworthy Breakthrough
- Growing Demand for PET to Drive Up Demand
- Introduction of SPECT/CT & PET/CT: Double Edged Weapons for Growth
- Manufacturers Quick to Take Cue
- Promising Developments in Therapeutic Radiopharmaceuticals Underway
- Targeted Peptides & Alpha Emitters: The New Frontiers of Therapeutic Radiopharmaceuticals
- International Collaborations Give a Thumbs Up to Drug Development
- Market Challenges
- High Costs of Drug Development Piques Manufacturers
- Supply Shortages: A Niggling Cause of Concern
- Table 1: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Weekly Demand by Region (includes corresponding Graph/Chart)
- Table 2: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Production by Reactor (includes corresponding Graph/Chart)
- Price Sensitivity & Competition from Alternatives Limit Market Potential
- Lack of Dosage Standards for Pediatric Patients' Limits Radiopharmaceutical Efficacy
- Unfounded Fears of Radiation Exposure Hinder Growth
- Bottlenecks in Developing Markets
3. PRODUCT OVERVIEW
- Nuclear Medicine: A Prelude
- Radiopharmaceuticals: A Definition
- Mechanism of Action
- Application of Radiopharmaceuticals
- Classification of Radiopharmaceuticals
- Diagnostic Radiopharmaceuticals
- Commonly Used Diagnostic Radiopharmaceutical Agents
- Major Isotopes and their Diagnostic Applications
- Advantages
- Classification
- Fluorodeoxy Glucose (FDG): A Rapidly Growing Diagnostic Radiopharmaceutical
- Molecular Imaging Modalities In Radiopharmaceutical Diagnostics
- Planar Imaging
- PET: A Prime Growth Driver for FDG
- Advantages
- Applications of PET
- Commonly used Radioisotopes in PET Scans
- Major PET Isotopes and their Applications
- Single Photon Emission Computed Tomography (SPECT)
- Applications of SPECT
- Commonly used Radioisotopes in SPECT Scans
- Therapeutic Radiopharmaceuticals
- Characteristics of Therapeutic Radiopharmaceuticals
- Commonly used Therapeutic Agents
- Major Isotopes and their Therapeutic Applications
- Radiopharmaceuticals for Thyroid Therapy
- Radiopharmaceuticals for Cancer Therapy
- Radiopharmaceuticals for Radiosynoviorthesis Therapy
- Radiopharmaceuticals for Bone Pain Palliation Therapy
- Radiopharmacy: A Key Link in the Distribution Chain
- Table 3: US Radiopharmacies Market (2010): Percentage Share Breakdown of SPECT Doses Sold by Company (includes corresponding Graph/Chart)
4. PRODUCT INNOVATIONS/INTRODUCTIONS
- Positron to Launch PosiRx
- Positron to Develop Indium Oxine
- GE Healthcare Enhances Radiopharmaceuticals Product Portfolio
- IBA Molecular Obtains Positive Opinion to Market Dopacis in Europe
- Bhabha Atomic Research Centre Develops Radiopharmaceuticals for Cancer Treatment
- Medrad Mounts Intego(tm) PET Infusion System at UPMC
- IBA Molecular Announces the Launch of Cyclone (r) 18 Twin
- Immunomedics Announces Pre-Clinical Results for its Combination Radioimmunotherapy
- Molecular Insight Develops New Radioiodinated Molecules
- Immunomedics Develops New Antibody for Radioimmunotherapy
5. RECENT INDUSTRY ACTIVITY
- Novelos Therapeutics Pockets Cellectar Inc
- Southern Research Institute Inks Agreement with Biomedical Research Foundation
- IBA Acquires Minority Stake in PET Net Solutions
- Covidien Enters into Agreement with IAE POLATOM
- Dalat Nuclear Research Institute Inks Agreement with Probactive Biotech
- Principio Wins Licensing Agreement from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
- Covidien Inks Definitive Agreement with Triad Isotopes
- Eli Lilly Inks Merger Agreement with Avid Radiopharmaceuticals
- Lumiphore Inks Agreement with Algeta
- IBA Renews Contract with Servicio Andaluz de Salud
- Lumiphore and Algeta Ink Partnership Agreement
- Positron and Covidien Ink Agreement
- PETNET Solutions Expands PET Radiopharmaceutical Network
- Triad Isotopes Acquires Radiopharmacy Network of Covidien
- Principio Receives Exclusive Technological Development License from Hopkins Sidney Kimmel Comprehensive Cancer Center
- PETNET Solutions Renews Supply Agreement with Paul Strickland Scanner Centre
- IBA Molecular Obtains Marketing Approval for Filtracis Radiopharmaceutical Kit
- DHA Inks MoU with DCD
- Algeta Signs Agreement with Bayer
- TAEK to Establish Proton Accelerator Facility
- Antisoma Collaborates with Bryan Oncor
- Karpov Institute Enters into Collaboration with MDS Nordion
- MDS Nordion Establishes Glucotrace Facility
- Draximage Inks Agreement with Guerbet
- Eczacybathorny-Monrol Collaborates with IBA
- Safran Obtains EU Nod for GEHP Take Over
- Siemens Healthcare Signs Agreement with Calypso Medical
- IBA Molecular to Purchase Interest in BMI
- Molecular Insight Signs Agreement with BioMedica Life Sciences
- Bayer Schering Signs Agreement with Algeta
- IBA Inks Agreement with Aposense
- Draxis Receives Approval from Health Canada for Generic Sestamibi
- Cyclopharm and Alfred Health Solutions Form Joint Venture
- Guerbet Inks Distribution Agreement with Draximage
- Ion Beam Applications Collaborates with EczacIbasI-Monrol Nuclear Products
- Positron Concludes Dose Shield Acquisition
- Positron Licenses NuView to Sell Imaging Technologies and Dose Dispensing Devices
- Bracco Imaging, Marillion Pharmaceuticals to Develop Novel Cancer Treatment
- EUSA Pharma Concludes Cytogen Acquisition
- AMIC, CRS to Co-Produce Indium-111
- AMIC, MU Partner to Produce Radioisotopes
- Bracco, Lantheus to Co-Promote CardioGen-82(r)
- Cell Therapeutics Submits sBLA for Use of Zevalin(r) in First-Line Therapy
- ANSTO, Siemens Ink $10m Partnership Deal
- Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging Kit
- Neoprobe, Draximage Collaborate Over Lymphoseek Distribution
- GE Healthcare Gets FDA Nod For New PET/CT Scanner
- GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal
- CIS-US Receives FDA Approval for Generic Choletec(r) Kit
- Cellectar Obtains Funds for Clinical Trials
- Lantheus Medical Completes Phase I Study Of Novel PET Imaging Tracer
- GE Healthcare, Cardinal Health Partner for Myoview(tm) Imaging Agent
- Avista Capital Partners Acquires Medical Imaging Unit of Bristol-Myers
- Siemens Healthcare Opens Two Radiopharmacies in US
- Cardinal Health Plans to Offer Services to Support PET Clinical Trials
- MEDRAD Associates with PETNET to Ingeniously Deliver FDG
- Triad Isotopes to Build Four Nuclear Pharmacies
- AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals
- NuView Signs Agreement with California University
- NuView Inks Exclusive Agreement with Philadelphia's Jefferson University
- University of Missouri Health Care Enters Sole-Source Supply Contract with Mid-America Isotopes
- Cardinal Health Expands Manufacturing Capabilities for PET Imaging Agents
- Jubilant Completes Draxis Acquisition
- Atomic Energy Closes Two Reactors
- IBA Plans to Acquire CIS BIO
- Ion Beam Announces Closure of TAEK Financing
- IBA Receives Approval for New Radiopharmaceutical Production Facility in UK
- WILEX AG Signs Licensing and Marketing Deal with Ion Beam
- Ion Beam Partners with Lantheus to Distribute Neurolite(r), Cardiolite(r) in Europe
- EIS Eczacibasi to Acquire 50 Percent Stake in Monrol
- Siemens to Set up Multiple Radiopharmaceutical Facilities in India
- Siemens Plans to Establish Its First Molecular Imaging Centre in India
- Ion Beam, Hae Dong Expands South Korea's PET Radiopharmaceutical Market
- Bayer and FutureChem Enter Radiolabeling Technology Licensing Agreement
- Cyclopharm Signs Agreement to Establish PET Radiopharmacy
- R2 Solucoes to Produce FGD-18, Radiological Diagnostics
6. FOCUS ON SELECT PLAYERS
- Actinium Pharmaceuticals, Inc. (US)
- Advanced Medical Isotope Corporation (US)
- Alseres Pharmaceuticals, Inc (US)
- Bayer HealthCare Pharmaceuticals (US)
- Bio-Nucleonics, Inc. (US)
- Bracco Diagnostics, Inc. (US)
- Cardinal Health, Inc (US)
- Covidien Imaging Solutions (US)
- EUSA Pharma (Europe) Ltd. (UK)
- Jubilant DraxImage Inc. (Canada)
- GE Healthcare Limited (UK)
- GlaxoSmithKline Plc (UK)
- IBA Group (US)
- Immunomedics, Inc. (US)
- Lantheus Medical Imaging, Inc (US)
- Nordion (Canada)
- Molecular Insight Pharmaceuticals, Inc. (US)
- Novelos Therapeutics Inc (US)
- Peregrine Pharmaceuticals, Inc. (US)
- PETNET Pharmaceuticals, Inc. (US)
- Pharmalucence, Inc. (US)
- Spectrum Pharmaceuticals, Inc. (USA)
- Triad Isotopes, Inc. (US)
7. GLOBAL MARKET PERSPECTIVE
- Table 4: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 5: World Historic Review for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 6: World 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 7: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 8: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 9: World 15-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 10: World Recent Past, Current & Future Analysis for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 11: World Historic Review for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 12: World 15-Year Perspective for Therapeutic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for 2003, 2010 & 2017 (includes corresponding Graph/Chart)
8. THE UNITED STATES
- A. Market Analysis
- Outlook
- Industry Structure
- Dependence On Imports
- Regulatory Scenario
- Thorny Regulations Dampen Down New Product Development
- FDA's Antidote
- Radiopharmaceutical Reimbursement in the US: Who's Under the Umbrella
- Diagnostic Radiopharmaceuticals Bundled As Supplies Under Medicare Reimbursements
- CMS Proposed Packaging of Zevalin & Bexxar into Diagnostic Radiopharmaceuticals Raises Eyebrows
- Implications
- Recommendations
- Changes in Medicare Reimbursements Vetoed
- CMS Proposes New HOPPS Guidelines for 2012
- (i) Reimbursement Rates for Nuclear Cardiology Procedures:
- (ii) Reimbursement Rates for Radiopharmaceuticals
- HOPPS Final Rule for 2011
- (i) Reimbursement Rates for PET Imaging
- (ii) Reimbursement Rates for Radiopharmaceuticals
- HOPPS Guidelines for 2008
- (i) Bundling Radiology Drugs and Services
- (ii) Payment for Therapeutic Radiopharmaceuticals
- (iii) PET/CT scans
- (iv) Cardiac CT and Coronary CTA Procedures
- (v) Conversion factor
- Reimbursement Issues for PET
- PET Clinical Applications Reimbursed by CMS as of March 2008
- Deficit Reduction Act (DRA) 2005: Creating a Storm in a Teacup
- Impact of the DRA On Outpatient Imaging Centers: An Evaluation
- Market Overview
- Sanguine Growth On Cards
- Expanding Diagnostic Applications Will Stimulate Future Growth
- Nuclear Cardiology Products Drive Up Diagnostic Radiopharmaceuticals Market
- Cardiovascular Imaging To Lead Volume Growth
- Cardiolite Loses Market Share to Generics
- Table 13: US Diagnostic Radiopharmaceutical Agents Market (2010): Percentage Share Breakdown of Procedure Volume by Imaging Procedure - SPECT and PET (includes corresponding Graph/Chart)
- Table 14: US Market for Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)
- Table 15: US Market for Cardiology Diagnostic Radiopharmaceuticals (2010): Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent - Cardiolite, Myoview, Thallium, and Sestamibi (includes corresponding Graph/Chart)
- New Oncology, Neurology Agents to Boost Diagnostic Radiopharmaceuticals Market
- Table 16: US Market for Non-Cardiology Diagnostic Radiopharmaceuticals Agents (2010): Percentage Share Breakdown of Value Sales for Oncology and Non-Oncology Applications (includes corresponding Graph/Chart)
- Installed Base of SPECT Scanners
- Table 17: Diagnostic Radiopharmaceutical Market in North America: Installed Base for SPECT and SPECT/CT Scanners in Units for Years 2006, 2008, 2010, 2012 & 2014 (includes corresponding Graph/Chart)
- Installed Pet Scanners in US
- US FDG Market
- Table 18: US FDG Market (2010): Percentage Share Breakdown of Procedure Volume by Procedure Type - Oncology, Neurology and Cardiology (includes corresponding Graph/Chart)
- Focused R&D Efforts will Fuel Therapeutic Radiopharmaceuticals Market
- Market Share Statistics
- Table 19: US Market for Diagnostics Radiopharmaceuticals Agents (2010): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart)
- Table 20: US Market for Therapeutic Radiopharmaceuticals (2010): Percentage Share Breakdown of Value Sales by Key Radiotherapeutics - Bone Palliation, Non-Hodgkin's Lymphoma, Hyperthyroidism /Thyroid Cancer and Others (includes corresponding Graph/Chart)
- Table 21: US Market for Therapeutic Radiopharmaceutical Agents (2010): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart)
- Table 22: US Market for Radiopharmaceutical Bone Palliation Procedures (2010): Percentage Share Breakdown by Key Radiotherapeutics - Metastron, Quadramet and Sr-89 (includes corresponding Graph/Chart)
- Table 23: Radiopharmacy Market in the US (2010): Percentage Breakdown of Revenues Generated by General Radiopharmacies and FDG Radiopharmacies (includes corresponding Graph/Chart)
- Product Launches
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 24: US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 25: US Historic Review for Radiopharmaceuticals for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 26: US 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
9. CANADA
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 27: Canadian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 28: Canadian Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 29: Canadian 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
10. JAPAN
- Market Analysis
- Table 30: Japanese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 31: Japanese Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 32: Japanese 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
11. EUROPE
- A. Market Analysis
- Outlook
- Competitive Scenario
- Key Statistics
- Table 33: European Radiopharmaceuticals Market (2010): Percentage Share Breakdown of Revenues by Company (includes corresponding Graph/Chart)
- Table 34: European Diagnostic Radiopharmaceuticals Market (2012): Percentage Share Breakdown of Value Sales by Imaging Modalities - SPECT and PET (includes corresponding Graph/Chart)
- Market Trends
- New Applications and Products Augur Good Market Prospects
- Increasing PET and PET/CT Applications Will Kindle Growth
- B. Market Analytics
- Table 35: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 36: European Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 37: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 38: European Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 39: European 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
- Table 40: European 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
11a. FRANCE
- A. Market Analysis
- Outlook
- Strategic Corporate Development
- B. Market Analytics
- Table 41: French Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 42: French Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 43: French 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
11b. GERMANY
- A. Market Analysis
- Outlook
- Strategic Corporate Development
- B. Market Analytics
- Table 44: German Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 45: German Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 46: German 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
11c. ITALY
- A. Market Analysis
- B. Market Analytics
- Table 47: Italian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 48: Italian Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 49: Italian 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
11d. THE UNITED KINGDOM
- A. Market Analysis
- Outlook
- Market Overview
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 50: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 51: UK Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 52: UK 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
11e. SPAIN
- Market Analysis
- Table 53: Spanish Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 54: Spanish Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 55: Spanish 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
11f. REST OF EUROPE
- A. Market Analysis
- Outlook
- Market Overview
- Product Launches
- Strategic Corporate Developments
- B. Market Analytics
- Table 56: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 57: Rest of Europe Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 58: Rest of Europe 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
12. ASIA-PACIFIC
- A. Market Analysis
- Outlook
- Product Launch
- Strategic Corporate Developments
- B. Market Analytics
- Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 60: Asia-Pacific Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 61: Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
13. REST OF WORLD
- A. Market Analysis
- Outlook
- Strategic Corporate Developments
- B. Market Analytics
- Table 62: Rest of World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
- Table 63: Rest of World Historic Review for Radiopharmaceuticals by Product Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
- Table 64: Rest of World 15-Year Perspective for Radiopharmaceuticals by Product Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
|
 |
